-
A Look at Developing Trends
Biosimilars, Machine Learning, Regulation, and More
In this issue, we highlight examples of our work and analysis in a number of notable fields in the middle of rapid change.
Analysis Group experts from the Health Care practice offer insights into developing trends in health care economics and outcomes research and litigation, including biosimilars introduction, the use of machine learning in health care litigation, regulatory approval processes and guidelines, and the economic costs of schizophrenia and obesity.
-
Health Care Bulletin
The Biosimilar Revolution Is Just Beginning in the US
The entry of biosimilars to the US market could be a significant event, but adoption may be more gradual than was seen with the rapid shift to generics.
-
Health Care Bulletin
Viewing Recent Opioid Regulations in Context
Analysis Group experts analyze some of the potential implications of new CDC guidelines for prescribing opioids.
-
Health Care Bulletin
Economic Burden of Schizophrenia in the US Exceeded $155 Billion in 2013
An Analysis Group report concludes that increased family intervention for schizophrenia patients can be beneficial, but has a high economic cost.
-
Health Care Bulletin
Machine Learning Algorithms in Health Care Litigation
Attorneys can leverage machine learning to deal with the growing volume and complexity of health care data.
-
Health Care Bulletin
The Myth of “Price Disconnects” in U.S. Pharma Markets
The pharmaceutical market should not be singled out for failing to make price/quality trade-offs when introducing “new and improved” versions of brand products.
-
Health Care Bulletin
Payments to Doctors: Causal Inferences Require a Closer Look
An Analysis Group team responded to a ProPublica report’s provocative suggestion that doctors prescribe more drugs when paid by manufacturers.
-
Health Care Bulletin
Recent Trends in Affordable Care Act Insurance
Health insurers offering ACA plans must walk a fine line to offer mandated services while remaining profitable.
-
Health Care Bulletin
Evaluating Real-World Effectiveness in Prescription Coverages
Manager Darya Rose and affiliate Robert Navarro discuss ways to overcome the “evidence gap” in terms of real-world effectiveness of newly approved drugs.
-
Health Care Bulletin
New Academic Affiliate: Dr. John E. Ware, Jr., Renowned PRO Expert
Dr. Ware, an internationally recognized leader in measuring Patient Reported Outcomes (PRO), has joined Analysis Group as an academic affiliate.
Also on analysisgroup.com
-
Recent Health Care Events and News
-
In 2016, Analysis Group’s Health Care practice was recognized as an industry leader at prominent international conferences in the U.S., Asia, and Europe.
Analysis Group presented a workshop, moderated an issue panel, and exhibited 18 posters at the 21st Annual International Meeting of the International Society for Pharmoeconomics and Outcomes Research (ISPOR). Research contributors included Managing Principals Mei Sheng Duh, Patrick Lefebvre, Edward Tuttle, Alan White, and Eric Wu; Vice Presidents James Signorovitch, Francis Vekeman, Jipan Xie, and Mihran Yenikomshian; Managers Wendy Cheng, Lynn Huynh, Nick Li, Elyse Swallow, and Hongbo Yang; and Senior Economists François Laliberté and Marie-Hélène Lafeuille.
Senior researchers gave three podium and four poster presentations at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), which brought together epidemiologists in the pharmaceutical, legal, and health insurance industries, as well as from academia. Research contributors included Managing Principals Mei Sheng Duh and Patrick Lefebvre; Vice President Francis Vekeman; Managers Wendy Cheng and Lynn Huynh; and Senior Economist François Laliberté.
Three of the posters supported by Analysis Group research were awarded medals at the Academy of Managed Care Pharmacy (AMCP) Nexus conference. The research, covering cardiac resynchronization therapy, Type 2 diabetes, and multiple sclerosis, was led by Managing Principals Mei Sheng Duh, Patrick Lefebvre, and Eric Wu, and Vice President James Signorovitch.
The Institute for Clinical and Economic Review (ICER), an independent nonprofit research organization, recently commissioned a report on the cost-effectiveness of treatments for moderate-to-severe plaque psoriasis. An Analysis Group team including Managing Principal Eric Wu, Manager Keith Betts, and Associate Junlong Li reviewed the preliminary results of ICER’s analysis, and identified and recommended a number of areas to improve.
Principal Howard G. Birnbaum and Managing Principal Paul E. Greenberg have edited Decision Making in a World of Comparative Effective Research, which is scheduled for publication by Springer in Spring 2017. The book provides a practical guide to decision makers in the life sciences industry who commission comparative effectiveness research (CER), including pharmaceutical, biologic, and device manufacturers, as well as both public and private payers.
-